1. Home
  2. PZZA vs GERN Comparison

PZZA vs GERN Comparison

Compare PZZA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Papa John's International Inc.

PZZA

Papa John's International Inc.

HOLD

Current Price

$20.72

Market Cap

1.2B

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.31

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZZA
GERN
Founded
1984
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
PZZA
GERN
Price
$20.72
$1.31
Analyst Decision
Buy
Hold
Analyst Count
8
3
Target Price
$45.00
$2.17
AVG Volume (30 Days)
1.2M
8.8M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
51.85
EPS
0.46
N/A
Revenue
$2,068,421,000.00
$1,065,000.00
Revenue This Year
N/A
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
$44.70
N/A
Revenue Growth
14.07
N/A
52 Week Low
$20.53
$1.04
52 Week High
$55.74
$2.01

Technical Indicators

Market Signals
Indicator
PZZA
GERN
Relative Strength Index (RSI) 34.67 41.49
Support Level N/A $1.24
Resistance Level $24.25 $1.46
Average True Range (ATR) 0.77 0.08
MACD 0.09 -0.02
Stochastic Oscillator 35.44 10.71

Price Performance

Historical Comparison
PZZA
GERN

About PZZA Papa John's International Inc.

Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: